PROF. IÑIGO LASA

Supervisor

Currently: Professor of Microbiology at UPNA, and Director of Navarrabiomed, a biomedical research center of the regional health service (https://www.navarrabiomed.es/en) (2015- ). Member of the European Academy of Microbiology (https://fems-microbiology.org/european-academy-of-microbiology/ ). He received the “Jaime Ferran” award for his research in Microbiology (2005), a biannual prize awarded by the Spanish Society of Microbiology and the Research award on Basic Science from UPNA (2006). He co-founded the biotechnology company Recombina in 2012 with members of his laboratory (https://www.recombina.com/es/ ). I. Lasa has an established record for high-quality supervision of PhD students (18) based on daily meetings with the PhD to monitor the research progress.

Previously: He did his postdoctoral training in the laboratory of Professor Pascale Cossart at the Institut Pasteur, where he focused his research on genetics of Listeria monocytogenes actin-based motility (1995-1997). He did a sabbatical stage in the laboratory of T. Gingeras at Cold Spring Harbor Laboratory (2009-2010) applying new transcriptome technologies to Staphylococcus aureus. Director of the Agrobiotechnology Center (UPNA-CSIC) (2010-2013). Assistant professor of Microbiology at Universidad Publica de Navarra (1998-2008)

Metrics: 50 (Scopus Author ID: 7003887382), >7600 cites

DR. MARIA PEÑAS

Co-Supervisor

I&R Director and co-founder of the biotechnology company RECOMBINA S.L. (Pamplona) since 2013. PhD in Biology (1999) and previous international postdoctoral researcher experience at Imperial College of London (2005-2006), Max Planck Institute in Germany (2001), University of Ancona Italy (2000), and as Researcher Professor at UPNA (1999-2011). She has been involved in numerous R&D projects developed for private companies, universities and research centers. Some international collaborations and interdisciplinary projects are for instance: “Strategic development of CAR-T therapies for the treatment of hematological and solid tumors (DESCARTHeS)”, “Development of a new technology for the production of vaccines based on heterologous membrane vesicles for the control of viral diseases”, “Development of new tools and strategies for the manipulation of species of the Pasteuralaceae genus (GENTOOLS)”, “Development of new strategies for the control of nocosomial diseases INNOECO)”, “Design and development of new biofertilizer formulations based on microbial  biofilms and (INBIOFER) and “Development of a new drug discovery platform based on two component systems (TCSS) as new anti-virulence targets for Staphylococcus aureus (NEOTEC))”.

FELIPE CAVA

Co-Supervisor

Department of Molecular Biology, Umea University. Director of the Cava Lab, part of the Molecular Medicine Sweden Umea Centre for Microbial Research. Supervisor of 8 postdocs and 4 PhDs. Research experience in the major “Achilles heels” of bacteria – their cell wall – both in terms of scientific fundamental questions and to improve therapies for longstanding and emerging infectious diseases, by means of advanced analytical technologies and cell imaging tools, combined with genetics and next generation sequencing technologies, biochemistry, bioinformatics and molecular biology. The lab is currently composed of 8 postdocs, 4 PhD students and 2 master students.

Welcome to the Cava Lab website